BioAtla, Inc. (BCAB)

BioAtla, Inc.'s stock has experienced significant volatility and a notable decline in the past six months. The share price was $0.86 as of November 24, 2025, a 48.37% decrease from November 25, 2024. Key events include the Q3 2025 earnings report with a net loss of $15.8 million, Q2 2025 financial results showing a narrowed loss, a workforce reduction in March 2025, strategic partnership discussions, and clinical program progress. Delays in product launches have negatively impacted revenue projections.

As a clinical-stage biopharmaceutical company, BioAtla, Inc.'s revenue generation is primarily tied to collaboration agreements rather than direct product sales, so traditional demand seasonality is not directly applicable. The company's financial performance is influenced by the progress of its clinical programs, achievement of milestones, and securing new strategic partnerships.

BioAtla, Inc. is a global clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancer, operating within the Health Care sector and Biotechnology industry. Its core technology is the Conditionally Active Biologics (CABs) platform, which designs antibodies to be active in the acidic environment of the tumor microenvironment. Major product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), Evalstotug (BA3071), BA3182, BA3361, BA3142, and a preclinical candidate for CAB-Nectin 4 x CAB-CD3.

BioAtla, Inc. has a global presence with operations in San Diego, California, where it is headquartered, and in Beijing, China, through a contractual relationship with BioDuro-Sundia.

BioAtla's brand reputation has been shaped by its commitment to innovative cancer therapies and clinical pipeline progress, alongside financial challenges. Positive influences include its innovative CAB technology, promising clinical data, and strategic partnerships. Negative influences include financial challenges, product launch delays, and stock price performance.

BioAtla, Inc.'s ownership structure includes institutional, insider, and retail investors. Major institutional shareholders include Acorn Capital Advisors, Llc, Vanguard Group Inc, and Tang Capital Management Llc. Carolyn Anderson Short is the largest individual shareholder, and Jay M. Short, co-founder and CEO, also owns a significant number of shares. Insiders hold approximately 9.35% of the company's stock, while retail investors hold a significant portion.